scholarly journals The new views on the state of the gut microbiota in obesity and diabetes mellitus type 2

2019 ◽  
Vol 22 (3) ◽  
pp. 253-262
Author(s):  
Elena V. Pokrovskaya ◽  
Minara S. Shamkhalova ◽  
Marina V. Shestakova

Obesity is a worldwide problem of the last century, the prevalence of which has reached pandemic proportions in developed countries. Over the past few years, a considerable amount of data has been gathered, reporting a direct link between changes in gut microbiota and the development of obesity, as well as related diseases, primarily, diabetes mellitus type 2. The elaboration of optimal methods of prevention and treatment regimens of these diseases needs to structure the existing knowledge about the mechanisms of development of metabolic disorders, the role of intestinal microbiota in the latter and possible therapeutic targets. This review examines the role of microorganisms in the human body, with the main focus on the developmental origins of metabolic disorders using animal models and accumulated experience of research on their effects on the human body, and also discusses possible treatment options, including bariatric surgery, fecal microbiota transplantation, the use of pre- and probiotics and certain particular groups of glucose-lowering drugs.

2019 ◽  
Vol 22 (4) ◽  
pp. 403-404
Author(s):  
Elena V. Pokrovskaya ◽  
Minara S. Shamkhalova ◽  
Marina V. Shestakova

A corrigendum on The new views on the state of the gut microbiota in obesity and diabetes mellitus type 2 by Elena V. Pokrovskaya, Minara S. Shamkhalova, Marina V. Shestakova (2019). Diabetes Mellitus. 22(3). doi: 10.14341/DM10194There is an error on the page 255: "Moreover, in obese patients, the concentration of circulating LPS increases by 20%, and in patients with diabetes mellitus, it increases by 125%. LPS is transported from cells of the large intestine into the bloodstream through chylomicrons or through intercellular gaps in the intestinal wall; by forming a complex of CD14 with Toll-like receptor 4 of macrophages and endothelial cells, it causes the release of anti-inflammatory cytokines: namely, interleukin-1, interleukin-6 and tumour necrosis factor alpha ". Instead of " pro-inflammatory cytokines" was published " anti-inflammatory cytokines ".Literary source Dahiya DK, Renuka, Puniya M, et al. Gut Microbiota Modulation and Its Relationship with Obesity Using Prebiotic Fibers and Probiotics: A Review. Front Microbiol. 2017;8:563. doi: https://doi.org/10.3389/fmicb.2017.00563 is listed twice (№№ 7 and 13) in the list of references.The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.The original article has been updated.


Author(s):  
L. V. Zhuravlyova ◽  
Yu. D. Stoianova

The combination of diabetes mellitus type 2 and gout is common. It has been established that prolonged hyperuricemia leads to insulin resistance and suppresses the effects of insulin, which is why the study of pathogenetic links in the formation of metabolic disorders in synergistic pathologies is relevant. AMPK has been shown to be a regulator of cell energy balance, which plays an important role in preventing the development of insulin resistance. The purpose of this review is to determine the impact of AMPK on carbohydrate, lipid and purine metabolism in patients with diabetes mellitus type 2 and gout. The realization of the effects of AMPK on metabolic processes in the human body occurs in two main ways — inhibition of anabolism and stimulation of catabolism, which will be discussed in the article. It is advisable to consider the mechanisms of action of indirect activators of AMPK as potential components for the comprehensive treatment of patients with metabolic disorders. The mechanisms of activation and inhibition of AMPK are not investigated enough, but it is known that AMPK plays a significant role in the main metabolic processes in the human body. The mechanisms of cell sensitivity to most energy‑containing molecules and substances directly depend on the AMPK activation degree. The presence of these dependencies may be evaluated in the case of metabolic diseases. Thus, further study of the effects of AMPK and its influence on carbohydrate, lipid and purine metabolism is necessary, due to the possibility of predicting the formation of insulin resistance, the severity of diabetes mellitus type 2 in combination with gout, and optimizing treatment in patients with comorbid pathology.


2004 ◽  
Vol 89 (1) ◽  
pp. 61-70 ◽  
Author(s):  
Laura Maffei ◽  
Yoko Murata ◽  
Vincenzo Rochira ◽  
Gloria Tubert ◽  
Claudio Aranda ◽  
...  

We present the fourth case of an adult man (29 yr old) affected by aromatase deficiency resulting from a novel homozygous inactivating mutation of the CYP19 (P450arom) gene. At first observation, continuing linear growth, eunuchoid body proportions, diffuse bone pain, and bilateral cryptorchidism were observed. The patient presented also a complex dysmetabolic syndrome characterized by insulin resistance, diabetes mellitus type 2, acanthosis nigricans, liver steatohepatitis, and signs of precocious atherogenesis. The analysis of the effects induced by the successive treatment with high doses of testosterone, alendronate, and estradiol allows further insight into the roles of androgens and estrogens on several metabolic functions. High doses of testosterone treatment resulted in a severe imbalance in the estradiol to testosterone ratio together with the occurrence of insulin resistance and diabetes mellitus type 2. Estrogen treatment resulted in an improvement of acanthosis nigricans, insulin resistance, and liver steatohepatitis, coupled with a better glycemic control and the disappearance of two carotid plaques. Furthermore, the study confirms previous data concerning the key role of estrogens on male bone maturation, at least in part, and regulation of gonadotropin secretion. The biopsy of the testis showed a pattern of total germ cell depletion that might be due to the concomitant presence of bilateral cryptorchidism. Thus, a possible role of estrogen in male reproductive function is suggested but without revealing a direct cause-effect relationship. Data from this case provide new insights into the role of estrogens in glucose, lipid, and liver metabolism in men. This new case of aromatase deficiency confirms previous data on bone maturation and mineralization, and it reveals a high risk for the precocious development of cardiovascular disease in young aromatase-deficient men.


2019 ◽  
Vol 20 (20) ◽  
pp. 5058 ◽  
Author(s):  
Fernando Lizcano

Adipose tissue is traditionally categorized into white and brown relating to their function and morphology. The classical white adipose tissue builds up energy in the form of triglycerides and is useful for preventing fatigue during periods of low caloric intake and the brown adipose tissue more energetically active, with a greater number of mitochondria and energy production in the form of heat. Since adult humans possess significant amounts of active brown fat depots and its mass inversely correlates with adiposity, brown fat might play an important role in human obesity and energy homeostasis. New evidence suggests two types of thermogenic adipocytes with distinct developmental and anatomical features: classical brown adipocytes and beige adipocytes. Beige adipocyte has recently attracted special interest because of its ability to dissipate energy and the possible ability to differentiate themselves from white adipocytes. The presence of brown and beige adipocyte in human adults has acquired attention as a possible therapeutic intervention for metabolic diseases. Importantly, adult human brown appears to be mainly composed of beige-like adipocytes, making this cell type an attractive therapeutic target for obesity and obesity-related diseases, such as atherosclerosis, arterial hypertension and diabetes mellitus type 2. Because many epigenetics changes can affect beige adipocyte differentiation from adipose progenitor cells, the knowledge of the circumstances that affect the development of beige adipocyte cells may be important to new pathways in the treatment of metabolic diseases. New molecules have emerged as possible therapeutic targets, which through the impulse to develop beige adipocytes can be useful for clinical studies. In this review will discuss some recent observations arising from the unique physiological capacity of these cells and their possible role as ways to treat obesity and diabetes mellitus type 2.


2015 ◽  
Vol 14 (4) ◽  
pp. 19110-19116 ◽  
Author(s):  
L.M. Wollinger ◽  
S.M. Dal Bosco ◽  
C. Rempel ◽  
S.E.M. Almeida ◽  
D.B. Berlese ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document